MALVERN, Pa., Nov. 14 /PRNewswire-FirstCall/ -- Auxilium Pharmaceuticals, Inc., today announced that the Nasdaq Stock Market, Inc. (NASDAQ) will add the Company to the NASDAQ Biotechnology Index(R) effective with the opening of the market on Monday, November 20, 2006.
“We are very proud to be selected to join the NASDAQ Biotechnology Index,” said Mr. Armando Anido, Chief Executive Officer and President. “We believe that our inclusion in this index reflects the increased awareness in the investment community of our successful progress in growing our marketed testosterone replacement gel, Testim(R), and in advancing our company transforming lead pipeline candidate, AA4500, for three important indications with high unmet medical need.”
The NASDAQ Biotechnology Index was launched in 1993 and includes biotechnology and pharmaceutical companies listed on the NASDAQ National Market that meet index eligibility requirements for market value, average daily share volume and seasoning as a public company, among other criteria. The index is ranked on a semi-annual basis in May and November, and serves as the basis for the iShares Nasdaq Biotechnology Index(SM) Fund . For more information about the NBI, including eligibility criteria, visit http://www.nasdaq.com.
About Auxilium
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing to urologists, endocrinologists, orthopedists and select primary care physicians. Auxilium markets Testim(R) 1%, a topical testosterone gel, for the treatment of hypogonadism through its approximately 180-person sales and marketing team. Auxilium has four projects in clinical development. Auxilium believes that AA4500, an injectable enzyme, has completed Phase II of development for the treatment of Dupuytren’s contracture and is in Phase II of development for the treatment of Peyronie’s disease and Frozen Shoulder Syndrome (Adhesive Capsulitis). Auxilium’s transmucosal film product candidate for the treatment of overactive bladder (AA4010) is in Phase I of development. The Company is currently seeking a partner to further develop this product candidate. Auxilium has two pain products using its transmucosal film delivery system in pre-clinical development. Auxilium has rights to six additional pain products and products for hormone replacement and urologic disease using its transmucosal film delivery system, and options to all indications using AA4500 for non-topical formulations. For additional information, visit http://www.auxilium.com.
SAFE HARBOR STATEMENT
This release contains “forward-looking-statements” within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s inclusion in the NASDAQ Biotechnology Index and the impact thereof, the timing for the commencement of various clinical trials for Auxilium’s product candidates during 2006, and products in development for pain, urology and sexual health. All statements other than statements of historical facts contained in this release, including but not limited to, statements regarding future expectations, plans and prospects for the Company, statements regarding forward-looking financial information and other statements containing the words “believe,” “may,” “could,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” and similar expressions, as they relate to the Company, constitute forward-looking statements. Actual results may differ materially from those reflected in these forward-looking statements due to various factors, including general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries and those discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2005 and the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2006 under the heading “Risk Factors”, which is on file with the Securities and Exchange Commission (the “SEC”) and may be accessed electronically by means of the SEC’s home page on the Internet at http://www.sec.gov or by means of the Company’s home page on the Internet at http://www.auxilium.com under the heading “Investor Relations - SEC Filings.” There may be additional risks that the Company does not presently know or that the Company currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward- looking statements.
In addition, forward-looking statements provide the Company’s expectations, plans or forecasts of future events and views as of the date of this release. The Company anticipates that subsequent events and developments will cause the Company’s assessments to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward- looking statements should not be relied upon as representing the Company’s assessments as of any date subsequent to the date of this release.
Auxilium Pharmaceuticals, Inc.
CONTACT: James E. Fickenscher, Chief Financial Officer, AuxiliumPharmaceuticals, Inc., +1-484-321-5900, jfickenscher@auxilium.com; GregoryGin, Lazar Partners, Ltd., +1-212-867-1762, ggin@lazarpartners.com
